Nona Biosciences, a global biotechnology company, is at the forefront of cutting-edge technological advancements in the field. With a comprehensive range of services and a focus on fully human antibody solutions, Nona Biosciences is empowering global biotherapeutic innovation. In this article, we will explore the company’s core technologies, mission, and its commitment to providing a complete antibody discovery and development solution.
Core Technology: Harbour Mice® and Fully Human Antibody Platforms:
At the heart of nona Biosciences’ success lies its core technology, Harbour Mice®. This platform is responsible for generating fully human monoclonal antibodies in two heavy and two light chains (H2L2) format. Additionally, Nona Biosciences has developed the Harbour HCAb PLUSTM platform, which generates fully human heavy chain only antibodies (HCAbs). These breakthrough technologies have been clinically validated and provide remarkable versatility for a wide range of applications, including bi- and multi-specific antibodies, CAR-T, ADC, mRNA, and diagnostic imaging.
Antibody Discovery and Development Solutions:
Nona Biosciences offers a comprehensive one-stop solution for therapeutic antibody discovery, engineering, and development. Their services encompass antigen design, production, and cell line generation, as well as in vitro functional assays establishment. The company leverages the Beacon® Single B Cell Screening platform, which enables precise characterization and selection of high-quality antibodies. Furthermore, Nona Biosciences excels in recombinant antibody production, in vitro characterization, and in vivo PK/PD efficacy studies. Their expertise also extends to developability assessment, antibody engineering (including affinity maturation, liability engineering, and Fc engineering), and the development of bispecific antibodies.
Partnerships and Flexible Business Models:
Nona Biosciences recognizes the value of collaboration and offers flexible business models to maximize customer satisfaction. Their Harbour Mice® platforms (H2L2 and HCAb) have been extensively validated and widely adopted by both industry and academia. By embracing brilliant ideas and supporting their partners, Nona Biosciences builds a pathway to success, ensuring that innovative solutions reach the market efficiently.
Conclusion:
Nona Biosciences is a leading biotechnology company revolutionizing the field through its advanced technologies and fully human antibody platforms. With a total antibody discovery and development solution, Nona Biosciences aims to support biotech and pharmaceutical companies from idea to IND (Investigational New Drug). By leveraging their Harbour Mice® platforms and expertise in antibody engineering, they are driving global inventions of transformative next-generation drugs. Through partnerships and flexible business models, Nona Biosciences is empowering biotherapeutic innovation and making a significant impact in the field of biotechnology.